Clinical and pharmacologic phase I study of Cemadotin–HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer - Concepedia

Concepedia

Publication | Closed Access

Clinical and pharmacologic phase I study of Cemadotin–HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer

23

Citations

12

References

1998

Year

K. Mross, Wolfgang E. Berdel, H.H. Fiebig, Raja Velagapudi, I.-M. von Broen, Clemens Unger

Annals of Oncology

Advanced CancerNovel Antimitotic Peptide24-Hour InfusionMedicinePharmacologyPeptide TherapeuticAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyCancer Research

References

	Year	Citations

Page 1